Necrostatin-1

製品コードS8037

Necrostatin-1化学構造

分子量(MW):259.33

Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

サイズ 価格(税別) 在庫  
JPY 18100 あり
JPY 46800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(34)

製品安全説明書

TNF-alpha阻害剤の選択性比較

生物活性

製品説明 Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.
特性 A powerful tool for characterizing the role of necroptosis with characterized primary target.
ターゲット
RIP1 [1]
(293T cells)
490 nM(EC50)
体外試験

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MmHSR4VtdCCYaXHibYxqfHliQYPzZZk> MWe1NOKh|ryP MWGyOOKhcA>? NUfYRphRcW6qaXLpeJMhVU2VLXnu[JVk\WRiY3XscEBl\WG2aB?= MkC5NlY1PzJ5MkO=
MEFs  MkjSR4VtdCCYaXHibYxqfHliQYPzZZk> M36xR|Ex6oDLzszN MojVOFghcA>? Mn3HSG1UVw>? MlTvbY5pcWKrdIOgfnZCTC2ycn;tc5Rm\CCmZXH0bEBw\iCFTl;UN{1l\XCuZYTl[EBOTU[| NWTTU4xuOjZ2M{e3PFk>
BMDM  NYT5UGc{TnWwY4Tpc44hSXO|YYm= Mmq3NVDDqM7:TR?= MmWwN|DDqG2rbh?= MoXidJJwfGWldIOgZ4VtdHNiZoLvcUBVSUuLLXnu[JVk\WRiTFTIJJJmdGWjc3W= M4CwbFI3OzhzNkCx
NCI-H28 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn;LNVDDqM7:TR?= NWnqc5dJOjUEoHi= NGnZZ3lxemW4ZX70d{BFSVCHLXnu[JVk\WRicnXkeYN1cW:wIH;mJG5EUS2KMkigZ4VtdCC4aXHibYxqfHoEoB?= NU[1fJByOjZyMESxN|g>
MiaPaCa-2 NGXoOIRHfW6ldHnvckBCe3OjeR?= MnG2NlAh|ryP MVmyOEBp NFLKT|Nl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz MnvaNlYxODB4MEe=
BxPC-3 NF;oR5VHfW6ldHnvckBCe3OjeR?= MmfTNlAh|ryP M4GydVI1KGh? NEmwOnll\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz MWKyOlAxODZyNx?=
SGC-7901 MonPR4VtdCCYaXHibYxqfHliQYPzZZk> MnHnN|DDqM7:TR?= Ml7mNeKhcA>? M{exSZN2eHC{ZYPz[ZMhd3ijbHnwcIF1cW5vbXXkbYF1\WRiY3XscEBl\WG2aB?= Moi0NlU4PjdyN{[=
KMS-12-PE  Mn75R4VtdCCYaXHibYxqfHliQYPzZZk> M3;BNFYxKM7:TR?= NF3pRpk2KGh? NH3s[nZqdmirYnn0d{BUUEtvaX7keYNm\CClZXzsJIRm[XSq MWKyOVU{ODB7OB?=
L929-A  MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVX3e2w1PTEEoN88UeKh MWiyOEBp M1u3eIJtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? MlHnNlU{QTh3NEC=
L929-N  MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXzXR4lqPTEEoN88UeKh MWOyOEBp M4PHWoJtd2OtczDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? MWWyOVM6QDV2MB?=
L929-A  MV3GeY5kfGmxbjDBd5NigQ>? NHfmNlI2OMLizszNxsA> Mn;UNVIhcA>? NUfUPW1E[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC= MYqyOVM6QDV2MB?=
L929-N  NHHkdGVHfW6ldHnvckBCe3OjeR?= NUnH[5dVPTEEoN88UeKh M3HPTlEzKGh? NXziZWdo[myxY3vzJJRp\SClbHXheoFo\SCxZjDDZZNx[XOnLUOgZY5lKFCDUmC= NYrpWGlOOjV|OUi1OFA>
L929 NVvUWJAzTnWwY4Tpc44hSXO|YYm= M{HHN|UxyqEQvF5CpC=> NX\DO4duOTJiaB?= M4fSOIlvcGmkaYTzJHRPTs7zLXnu[JVk\WRiQnnkJINt\WG4YXfl MlzhNlU{QTh3NEC=
L929-A NYnHXW1YTnWwY4Tpc44hSXO|YYm= MVK1NOKh|ryPwrC= NYW4PIh7OTJiaB?= NGL1dXRqdmirYnn0d{B1cGViVF7G{tEucW6mdXPl[EBtd3O|IH;mJI1qfG:laH;u[JJq[WxibXXtZpJidmVicHXycYVi[mmuaYT5 MXGyOVM6QDV2MB?=
L929 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF7tO5g{OMLizszN M3;kdFHDqGh? MmXQbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=> M33udFI2ODl3N{Sy
L929 NGj0eFNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4K1O|MxyqEQvF2= MYOxxsBp M1K4T4lvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPs[YF3[WenIH;mJHRweG9iSR?= MoLSNlUxQTV5NEK=
Huh7 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIm4[VQ2OCEEtV2= M4SwNVI1NzR6IHi= MkHNSG1UVw>? MmmzdJJmfmWwdIOgZ4VtdCCmZXH0bEBw\iC{QXTIR3Yh[29vaX7m[YN1\WRiSIXoO{Bk\Wyucx?= MlXHNlQ6PzN{NEC=
OHC M1HOUGZ2dmO2aX;uJGF{e2G7 M3ixfVMxOOLCid88US=> NETmSYhFVVOR NWfvbVJ3cW6lcnXhd4V{KG6xaYPlMYlv\HWlZXSgZ49v\GWwc3XkJI52[2ynaR?= MVWyOFg4PDd|NB?=
OHC MXTGeY5kfGmxbjDBd5NigQ>? NGraR|c{ODEkgJpOwG0> MUnEUXNQ NGOyfmxl\WO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDze49tdGWwIH71Z4xmccLi MXqyOFg4PDd|NB?=
OHC NET5cYZHfW6ldHnvckBCe3OjeR?= MkO2N|Ax6oDLzszN M1j0O2ROW09? MoHpdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl NXvQVGtWOjR6N{S3N|Q>
OHC NVvDTmN{TnWwY4Tpc44hSXO|YYm= M{HZXVMxOOLCid88US=> MWPEUXNQ MlS0[IlucW6rc3jld{Bvd2m|ZT3pcoR2[2WmIFHNVGsh[WO2aY\heIlwdg>? NGTVcFQzPDh5NEezOC=>
OHC NWTkc3pSTnWwY4Tpc44hSXO|YYm= NXzZTJNlOzBy4pEJ{txO M2\pSmROW09? M3vJZ4lv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR|gh[W[2ZYKgco9qe2ViZYjwc5N2emV? MWWyOFg4PDd|NB?=
SK-Hep1 M2PqeGZ2dmO2aX;uJGF{e2G7 NGGz[VY3OOLCid88UeKh MWGxPQKBkWh? Mo\UZoxw[2u|wrFOtk1t[XCjY3jvcoUucW6mdXPl[EBud3KyaH;sc4dq[2GuIHPoZY5o\SxiY3XscEBl\WG2aDDhcoQhWElidYD0ZYtm M2THclI1QDN{NkCy
SK-Hep1 NUfkc4FuTnWwY4Tpc44hSXO|YYm= NGLkTZM3OOLCid88UeKh MX2xPQKBkWh? MnzXbY5pcWKrdIOg{tIuVGGyYXPoc45mNWmwZIXj[YQhdGWja3Hn[UBw\iCKTVfCMVHDqA>? NFGzOJYzPDh|Mk[wNi=>
SK-Hep1 MmGxSpVv[3Srb36gRZN{[Xl? M4r4blYx6oDLzszNxsA> NVnwTXk2OTkkgJno MoDwZoxw[2u|wrFOtk1t[XCjY3jvcoUudWWmaXH0[YQhWEGUIHHjZ5VufWyjdHnvckBidmRiQVnGJJRz[W6|bH;jZZRqd25idH:geIhmKGO7dH;zc4zDqA>? MUSyOFg{OjZyMh?=
L-540  MWnGeY5kfGmxbjDBd5NigQ>? NXq4RlZGPjEkgJpOwI0> M2\zZVHjiImq NH7LeYtxemW4ZX70d{B1cGViZ3Xu[ZJifGmxbjDv[kBTV1N? M1zMUFI1PTZzNUG5
L-540  NYnMe4t5TnWwY4Tpc44hSXO|YYm= NX;S[nd7PjEkgJpOwI0> NILoem4y6oDLaB?= MnfPdJJmfmWwdIOgeIhmKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? MmKwNlQ2PjF3MUm=
L-540  MkjXR4VtdCCYaXHibYxqfHliQYPzZZk> NVz6[ZpwPjEkgJpOwI0> NUfHXpZ4OeLCiXi= NYKx[W84emWmdXPld{B1cGViR3n2bY5we3SjdD;Tc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKGSnYYTo NH[0WWwzPDV4MUWxPS=>
AGS Ml;nR4VtdCCYaXHibYxqfHliQYPzZZk> MknoOlDjiIoQvH2= M2XSTVHjiImq M4LsVpBz\X[nboTzJJNpcWuxbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MV2yOFQ3OzF7OR?=
NRK-52E  MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGP0bWIzOCEQvF2= NYW2XHIyOjRiaB?= MnfPdJJwfGWldIOgZ4VtdHNiZoLvcUBk\WyuIHTlZZRpKGOjdYPl[EBjgSCrc3Po[Y1q[SCrbnr1dpk> M1\vW|I1OzVzOES1
NRK-52E  MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXuyNEDPxE1? NIT3bXgzPCCq MlL2bY5kemWjc3XzJINmdGxidnnhZoltcXS7IHHmeIVzKFSQRj5OtUBUfGmvdXzheIlwdiCjbnSgRXRRKESncHzleIlwdg>? NGC3bHEzPDN3MUi0OS=>
NRK-52E  NILDSmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmC5NlAh|ryP NE[we2czPCCq NGG0ZmtqdmirYnn0d{BqdmO{ZXHz[YQhTHKyMTDwdo91\WmwIHX4dJJme3Orb36gZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w M2P4VVI1OzVzOES1
L929 MojkSpVv[3Srb36gRZN{[Xl? M1rze|IwPcLizsznM41tyqB? M3Hjd|I1yqCq NUDQO2p4emW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> Mne2NlM6PDF5Nkm=
L929 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLzSZlCOi93wrFOwIcwdW{EoB?= NYjGO2RUOjUEoHi= MorQdoV3\XK|ZYOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZY5lKGOnbHyg[IVifGhiaX7keYNm\CCkeTDUUmbPuSCjbH;u[UBieyC5ZXzsJIF{KFSQRt8xxsAsyqC8VlHE MlL4NlM6PDF5Nkm=
L929 MYXGeY5kfGmxbjDBd5NigQ>? NHjOSFkzyqEQvHevcYzDqA>? MnHYNlTDqGh? NVTlVmJbeHKxbX;0d{Bk[XOyYYPlMVYhMHB{MDmgZYN1cX[rdImgZY5lKHC{b3Phd5Bie2VvNjDjcIVifmGpZR?= M2P3OlI{QTRzN{[5
L929 M{\zfmZ2dmO2aX;uJGF{e2G7 M2nVfFXDqM7:Zz;tcC=> NFfzc3QzPMLiaB?= MVHicI9kc3Niem\BSEBqdmS3Y3XkJI5m[3KxcITvd4l{KGGwZDDheZRweGijZ4m= MXyyN|k1OTd4OR?=
C6 Mo\ER4VtdCCYaXHibYxqfHliQYPzZZk> NFr2XFAyKG2vb3yvUC=> NXzuSW15OyCq MVPheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi= MlTxNlM5PDB2NEG=
U87 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX:xJI1ud2xxTB?= NVnQS3RoOyCq MVTheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi= NFr5PY4zOzh2MES0NS=>
C6 NHTxemFEgXSxdH;4bYNqfHliQYPzZZk> NITNTpYyKG2vb3yvUC=> MYKzJIg> Ml33Zoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? M3XmU|I{QDRyNESx
U87 NH\DNZpEgXSxdH;4bYNqfHliQYPzZZk> Mnn2NUBudW:uL1y= MYSzJIg> NV;CcHlU[myxY3vzJJNpcWuxbnnuJIlv\HWlZXSgcoVkem:|aYO= M1TWcFI{QDRyNESx
C6 MWjGeY5kfGmxbjDBd5NigQ>? MX[xJI1ud2xxTB?= MUKxMlUuOyCq NWPMSWY3e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCUSWCtNUBk[XW|ZXSgZpkhe2ira3;ubY4> MljwNlM5PDB2NEG=
U87 MWXGeY5kfGmxbjDBd5NigQ>? NU\udZo2OSCvbX;sM2w> NWPm[m5iOS53LUOgbC=> NGPRS5R{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKFKLUD2xJINifXOnZDDifUB{cGmtb37pci=> M{\vVFI{QDRyNESx
TE671 NFz3eYJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NG[yfpY1OOLCid88[{9udMLi NV7WRodJOjRiaB?= NYm4fXhKemW|Y4Xld{BIYDF3LUC3NE1qdmS3Y3XkJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHl? M3vybFI{PzR2Mkm2
RMS13 NHvYfoVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mo\TOFDjiIoQvHevcYzDqA>? NH3oRXIzPCCq Mn;NdoV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> MmDiNlM4PDR{OU[=
MEFs NYXPdZpzS3m2b4TvfIlkcXS7IFHzd4F6 NUD3XYJ6Oi94L{KwJO69VQ>? MoqzNVghcA>? NVLqUpBTcW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDj[YxtKGSnYYToJIlvKFKnbFGgT28hVUWIcx?= M37ZRlI{PzJ5NUix
MEFs NX36Rll7TnWwY4Tpc44hSXO|YYm= MUWyNOKh|ryP NYfvOJRmOS9{L{SgbC=> M4XufJN2eHC{ZYPz[ZMhXE6IzsGtbY5lfWOnZDDSTXBMOSCyaH;zdIhwenmuYYTpc44> MYmyN|czPzV6MR?=
ΔN-Karpas 299  MYLDfZRwfG:6aXPpeJkhSXO|YYm= Mk[yNlDDqM7:TR?= MXmxOkBp NGC0XWdqdmirYnn0d{BETDNyLXnu[JVk\WRiY3XscEBl\WG2aB?= M1HTUlI{PTR3OUO4
MM.1S  MY\DfZRwfG:6aXPpeJkhSXO|YYm= NWDHVXY5QTBiwsXN NF7VWXMyKGh? M2Phb4Jtd2OtczDCRXkhOTFvN{C4NkBqdmS3Y3XkJJJieGmmIHPlcIwhe3enbHzpcoc> MmLRNlM2OjdzNUS=
KMS-12-BM MVnDfZRwfG:6aXPpeJkhSXO|YYm= MlntPVAhyrWP NXr2eXc2OSCq NHy1fWdjdG:la4OgRmF[KDFzLUewPFIhcW6mdXPl[EBz[XCrZDDj[YxtKHO5ZXzsbY5o NHfPUZIzOzV{N{G1OC=>
HT-22  NG[0SYhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVqxNOKh|ryP NXG2XGFTOTMEoHi= M1W3e2ROW09? MULwdo91\WO2czDh[4FqdnO2IHfseZRidWG2ZT3pcoR2[2WmIHPlcIwh\GWjdHi= MXyyN|MxPzd3Mh?=
HT-22  MWDGeY5kfGmxbjDBd5NigQ>? MnftNlXDqM7:TR?= NFvpUGox6oDVM{FCpI1qdg>? NEW0WIVFVVOR NFLrT4dqdmirYnn0d{BGWktiQXP0bZZifGmxbjDpcoR2[2WmIHL5JIdtfXSjbXH0[S=> MoLvNlM{ODd5NUK=
NIH3T3  MlzrSpVv[3Srb36gRZN{[Xl? NYrXfI5JOTBxNUCg{txO MnHwNU8{KGh? M4fVT4Fu\Wyrb4LheIV{KFSQRt8xMYRzcX[nbjDjc41xdGW6IH\vdo1ifGmxbh?= NH7KXokzOzJ4MU[3Oy=>
SH-EP NVzzU5o4SXCxcITvd4l{KEG|c3H5 MnLTNVDjiIoQvF5CpC=> NVvRTItVPzMkgJnoxsA> M2S0UIlvcGmkaYTzJGlCWCCrbnjpZol1d3JvIHHu[EBN\XijdIXteY1i[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NWTrUZpLOjJ6OUCzNlI>
HL60 Mn7ORZBweHSxc3nzJGF{e2G7 MlP2OlAh|ryP NEXCS|EyOiCq NHTBWo1mdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> M3yyT|IzQDN5Nki5
HL60/Adr NH;CVo5CeG:ydH;zbZMhSXO|YYm= NVT1VIRlPjBizszN NGezZ5AyOiCq NYrCe49R\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> NWrLd5NuOjJ6M{e2PFk>
K562 MmTrRZBweHSxc3nzJGF{e2G7 M1jvclYxKM7:TR?= NWHXSXJOOTJiaB?= NXv6UWRz\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MWKyNlg{PzZ6OR?=
K562/Adr  MmP2RZBweHSxc3nzJGF{e2G7 MX[2NEDPxE1? MXKxNkBp MmnG[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MnjJNlI5Ozd4OEm=
HL60 NFq2R4VHfW6ldHnvckBCe3OjeR?= M3rWfVYxKM7:TR?= MVuxNkBp NHr4d5VifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 NXfXOIt5OjJ6M{e2PFk>
HL60/Adr M3\vbWZ2dmO2aX;uJGF{e2G7 M33kfFYxKM7:TR?= MWexNkBp MoLMZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? M1rkeVIzQDN5Nki5
K562 M{T2U2Z2dmO2aX;uJGF{e2G7 M{XOOlYxKM7:TR?= NXvlbIdtOTJiaB?= NHHZdWpifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 MV6yNlg{PzZ6OR?=
K562/Adr  MVrGeY5kfGmxbjDBd5NigQ>? Mlm5OlAh|ryP NGHKcpcyOiCq M2HDT4F2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? NXTQPHZGOjJ6M{e2PFk>
HL60 M3PFe2Z2dmO2aX;uJGF{e2G7 Ml;XOlAh|ryP MVexNkBp NYf5ZoR{cW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 NUjKdpEyOjJ6M{e2PFk>
HL60/Adr NFHETlhHfW6ldHnvckBCe3OjeR?= MlnJOlAh|ryP MX:xNkBp MXHpcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? NIjCNo4zOjh|N{[4PS=>
K562 NXG4V|hYTnWwY4Tpc44hSXO|YYm= MorYOlAh|ryP NIfmcFUyOiCq NFrWZWNqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= Mm\kNlI5Ozd4OEm=
K562/Adr  NEHURmNHfW6ldHnvckBCe3OjeR?= NEiz[JY3OCEQvF2= MV6xNkBp NYDn[4xicW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 NEnCXG8zOjh|N{[4PS=>
L929sA NVq3O5RkSXCxcITvd4l{KEG|c3H5 NWL3fpA3OTBizszN M1LsWlEhcA>? NILRSpNqdmirYnn0d{B1cGViYYDvdJRwfGmlIILld5BwdnOnIITvJHRPTg>? M3\3UlIzOzZ{N{[3
L929sA MnzGRZBweHSxc3nzJGF{e2G7 M3HBVVExKM7:TR?= NUf4dJhWOSCq M2fQdJJme2O3ZYOgZ4VtdHNiZYjwdoV{e2mwZzDSTXBMOc7WSVSg[pJwdSCWTl[tbY5lfWOnZDDhdI9xfG:|aYO= NEjEUHAzOjN4Mke2Oy=>
L929sA MUnBdI9xfG:|aYOgRZN{[Xl? MWOxNEDPxE1? NU\rTpFlOSCq NV3ydVdK[WK{b3fheIV{KHSqZTDpcpRmemGldHnvckBw\iClYYPwZZNmNThid3n0bEBHSUSG NIP2cYUzOjN4Mke2Oy=>
TPC-1 NF75TmJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{jxSFExOCEQvF2= MVGyOEBp NGXRdZhFVVOR MVLpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= M{\UbFIzOTN4OEG4
8505c M1zhVmNmdGxiVnnhZoltcXS7IFHzd4F6 NYH0V4p2OTByIN88US=> MmfCNlQhcA>? MmXoSG1UVw>? M4iwPIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> MoewNlIyOzZ6MUi=
SW13 MnnXR4VtdCCYaXHibYxqfHliQYPzZZk> M4rwR|ExOCEQvF2= NIHR[o0zPCCq MnXlSG1UVw>? M2X0V4lv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> NGLoXXczOjF|NkixPC=>
Jurkat  NITWZZlEgXSxdH;4bYNqfHliQYPzZZk> NVvtOVhrPTBxIEGwNE8zODEEoN88cS=> MlnFNU8{KGh? NHjsXoZz\WS3Y3XzxsBP[WWpbHXybYEh\m:5bHXybU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NUXjTnExOjF3M{WwNlA>
Jurkat  MV3GeY5kfGmxbjDBd5NigQ>? MoPnNlAxyqEQvH2= NFTQPWk{OCCvaX6= MoX6doVlfWOnc9MgUoFm\2yncnnhJIZwf2yncnmtbY5lfWOnZDDy[YFkfGm4ZTDvfJlo\W5ic4DlZ4lmeyBqUl;TLUBo\W6ncnH0bY9v NGHIeI0zOTV|NUCyNC=>
HT-22 MXHDfZRwfG:6aXPpeJkhSXO|YYm= MonWNVAh|ryP NH7kXoYyOiCq NGXSRoRxem:2ZXP0d{Bi\2GrboP0JINmdGxiZHXheIghcW6mdXPl[EBjgSB3wrDtcY9tN0xiZ3z1eIFu[XSnwrC= NXexOHp1OTd5NkC4Olk>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

- 合併

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
細胞試験:

[2]

- 合併
  • 細胞株: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • 濃度: 0.01-100 μM
  • 反応時間: --
  • 実験の流れ:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (参考用のみ)

溶解度 (25°C)

体外 DMSO 51 mg/mL (196.66 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 259.33
化学式

C13H13N3OS

CAS No. 4311-88-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

TNF-alphaシグナル伝達経路

相関TNF-alpha製品

Tags: Necrostatin-1を買う | Necrostatin-1 ic50 | Necrostatin-1供給者 | Necrostatin-1を購入する | Necrostatin-1費用 | Necrostatin-1生産者 | オーダーNecrostatin-1 | Necrostatin-1化学構造 | Necrostatin-1分子量 | Necrostatin-1代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID